How does Semaglutide work?
GLP-1 receptor agonist resistant to DPP-4 enzymatic breakdown. Binds GLP-1 receptors in the brain (satiety), gut (delayed gastric emptying), and pancreas (glucose-dependent insulin secretion). Weekly dosing achieves steady-state GLP-1 signaling. In plain terms, Semaglutide is the original weight-loss wave, sold as Ozempic / Wegovy. A GLP-1 agonist. Mechanistic detail like this comes largely from preclinical and early research, the human picture is limited.
What people use it for
- Beginners to GLP-class peptides
- Users with insurance coverage on Wegovy / Ozempic
- Metabolic-syndrome adults under provider guidance
References
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1) — Wilding JPH et al., NEJM, 2021
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) — Lincoff et al., N Engl J Med, 2023
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) — Marso et al., N Engl J Med, 2016
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Semaglutide
Last updated 2026-06-06.